Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC

Exclusion Criteria

• •Compound small cell lung cancer and transformed small cell lung cancer.
• •Patients with brain metastases and neurological symptoms; Note: Subjects with previous imaging evidence of brain metastases who have undergone local treatment (such as radiotherapy or surgery) for intracranial metastases and have stable lesions for more than 28 days without symptoms can be enrolled.
• •Other primary malignant tumors other than small cell lung cancer (excluding non melanoma skin cancer, breast cancer in situ, cervical cancer in situ, and superficial bladder cancer, or other cancers that have been effectively controlled in the past three years and have no evidence of disease recurrence) were previously or currently combined.
• •Clinically significant cardiovascular diseases At the beginning of the study treatment, the toxicity associated with previous anti-tumor treatments did not recover to ≤ CTCAE grade 1, except for hair loss and peripheral neurotoxicity of CTCAE grade 2.
• •Known HIV infection (HIV antibody positive), active hepatitis B and C patients.
• •Receive chemotherapy, targeted therapy, radiotherapy, and biological therapy, with less than 4 weeks since the first administration in this study; Or have received local radiotherapy within 2 weeks.
• •Having undergone major surgery or significant traumatic injury within 28 days prior to the first administration of the investigational drug -